![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Through the acquisition, PMI will build its overall platform of R&D and manufacturing expertise in nicotine and beyond nicotine product areas through the addition of Fertin’s strong capabilities and skilled workforce.
Lead Product(s): Nicotine
Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed
Highest Development Status: N/AProduct Type: Small molecule
Partner/Sponsor/Collaborator: Philip Morris International
Deal Size: $820.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition September 15, 2021
Details:
Through the acquisition, PMI will build its overall platform of R&D and manufacturing expertise in nicotine and beyond nicotine product areas through the addition of Fertin’s strong capabilities and skilled workforce.
Lead Product(s): Nicotine
Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed
Highest Development Status: N/AProduct Type: Small molecule
Partner/Sponsor/Collaborator: Philip Morris International
Deal Size: $820.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition July 01, 2021